Hosted by HealthpointCapital
Hosted by HealthpointCapital
TendoNova is transforming the treatment of tendinopathy, a chronic condition affecting an estimated 6-9 million Americans each year, within a US market opportunity of approximately $1 billion. Its flagship product, the Ocelot, is a wireless orthopedic tool: an FDA-cleared, micro-invasive device built on exclusive technology licensed from Emory University and Georgia Institute of Technology, billed under established tenotomy procedure codes. Its reusable-driver model eliminates the capital-equipment barrier that has constrained competitor adoption, and clinical and registry data show an 85% reduction in patient-reported pain at six months with no adverse events. Operating on a capital-efficient razor-and-blade model with strong unit economics, TendoNova has paired FDA clearance and clinical outcomes data with consistent revenue growth every year since 2024, roughly tripling over that period and recently accerelating further. Backed by investors including the NFL Players Association, Georgia Research Alliance, and VentureSouth, TendoNova is scaling its commercial team and physician network across a large, underpenetrated market.
